FVC · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in interstitial lung disease – FVC (% predicted) A lower percentage… compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Pulmonary arterial hypertension · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Overall mortality · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in overall mortality compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Event‐free survival · people with systemic sclerosis
Autologous myeloablative selective HSCT showed no clear difference in event‐free survival compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Frequency of attacks Per week (over 2 weeks) · primary Raynaud's phenomenon
1 finding from 1 review
Severity of attacks · primary Raynaud's phenomenon
1 finding from 1 review
Duration of attacks per day (minutes) · primary Raynaud's phenomenon
1 finding from 1 review
QoL · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ measured over 8 weeks · primary Raynaud's phenomenon
It is very uncertain whether selective serotonin reuptake inhibitors changes adverse events (over 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
RCS · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
> 50% reduction in depressive symptoms · people with epilepsy and depression
1 finding from 1 review
Depressive symptoms · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Seizure frequency · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Treatment withdrawal · people with epilepsy and depression
It is very uncertain whether selective serotonin reuptake inhibitors changes withdrawals compared with cognitive behavioural therapy (very low certainty).
1 finding from 1 review
RR 0.44 [0.05, 3.85]
15 participants
Very low
Cognitive function · people with epilepsy and depression
1 finding from 1 review
Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Adverse effects ‐ adverse event profile · people with epilepsy and depression
1 finding from 1 review
Outcomes (2‐6 months post‐treatment) · adults with panic disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder
Selective serotonin reuptake inhibitors may leads to lower failure to respond compared with placebo (low certainty).
1 finding from 1 review